ArticleJournal of medical biochemistry2025
Differently expressed miRNA in plasma samples of immune thrombocytopenic purpura patients and its clinical significance.
Article in Journal of medical biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To guide clinical doctors, current work has been designed to explore the abnormal expressions of miRNAs in plasma samples of patients with immune thrombocytopenic purpura (ITP). Methods: Bioinformatic analysis was performed using the GSE80401 chip. The study subjects were recruited from the First People's Hospital of Lianyungang between May 2021 and December 2023. 48 ITP patients admitted to the intensive care unit were enrolled. miRNA levels were examined using real-time polymerase chain reaction. All data were analysed using SPSS 22.0 software. The potential diagnosis value of the significantly up-regulated and down-regulated miRNAs was evaluated using a receiver operator characteristic (ROC) curve. Results: We performed bioinformatical analysis on the GSE80401 chip and identified the differently expressed miRNAs in ITP patients compared to the controls, and the results of the heat map showed the results. GO and pathway analysis revealed the process that involved the differently expressed miRNAs. Next, the results of RT-qPCR analysis showed the levels of miR-877-3p, miR-425-3p, miR-122-5p, miR-1281, and miR-1825 were significantly increased. In contrast, the miR-3945, miR-4430, miR-3158-5p, miR-3131, and miR-4655-3p levels were markedly decreased in plasma samples of ITP patients compared with the controls. Finally, results showed that the area under the ROC curve of miRNAs was as follows: miR-877-3p, 0.9349, miR-425-3p, 0.8607, miR-1281, 0.7131, miR-1825, 0.8928, miR-3945, 0.8459, miR-4430, 0.8112, miR-3158-5p, 0.6059, miR-3131, 0.8989, suggesting that the above miRNAs may serve as biomarkers for distinguishing the ITP patients from healthy controls. Conclusions: miRNAs may have predictive value for the diagnosis of ITP. The results of current work may provide new clues for the pathogenesis of ITP, which in turn offers a new theoretical basis and therapeutic tools for the clinical diagnosis and treatment of ITP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.